Utility of the number needed to treat in paediatric haematological cancer randomised controlled treatment trials: a systematic review

BMJ Open
Haroon HasanA Fuchsia Howard

Abstract

The primary objective was to assess the utility of the number needed to treat (NNT) to inform decision-making in the context of paediatric oncology and to calculate the NNT in all superiority, parallel, paediatric haematological cancer, randomised controlled trials (RCTs), with a comparison to the threshold NNT as a measure of clinical significance. Systematic review DATA SOURCES: MEDLINE, EMBASE and the Cochrane Childhood Cancer Group Specialized Register through CENTRAL from inception to August 2018. Superiority, parallel RCTs of haematological malignancy treatments in paediatric patients that assessed an outcome related to survival, relapse or remission; reported a sample size calculation with a delta value to allow for calculation of the threshold NNT, and that included parameters required to calculate the NNT and associated CI. A total of 43 RCTs were included, representing 45 randomised questions, of which none reported the NNT. Among acute lymphoblastic leukaemia (ALL) RCTs, 29.2% (7/24) of randomised questions were found to have a NNT corresponding to benefit, in comparison to acute myeloid leukaemia (ALM) RCTs with 50% (3/6), and none in lymphoma RCTs (0/13). Only 28.6% (2/7) and 33.3% (1/3) had a NNT that was less tha...Continue Reading

References

Jun 30, 1988·The New England Journal of Medicine·A LaupacisR S Roberts
Feb 18, 1995·BMJ : British Medical Journal·R J Cook, D L Sackett
May 1, 1997·Annals of Internal Medicine·H J McQuay, R A Moore
Nov 7, 1998·BMJ : British Medical Journal·D G Altman
Dec 3, 1999·BMJ : British Medical Journal·D G Altman, P K Andersen
Jun 1, 2002·JAMA : the Journal of the American Medical Association·Jim NuovoDenise Chang
Jul 23, 2002·Journal of General Internal Medicine·Malcolm Man-Son-HingGeorge Wells
Jan 30, 2004·The New England Journal of Medicine·Pierre J MeunierJean-Yves Reginster
Apr 14, 2005·World Journal of Surgery·Martin R Tramèr, Bernhard Walder
Sep 10, 2008·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Finlay A McAlister
Feb 4, 2009·Journal of the American Geriatrics Society·Frank J MolnarDean Fergusson
Feb 18, 2009·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Larry F EllisonUNKNOWN Canadian Cancer Society's Steering Committee for Canadian Cancer Statistics
Mar 24, 2009·BMC Medical Research Methodology·Mandy HildebrandtRalf Bender
Nov 3, 2009·Journal of Clinical Epidemiology·Andreas StangRalf Bender
Mar 25, 2010·BMJ : British Medical Journal·David MoherDouglas G Altman
Aug 6, 2011·Journal of Clinical Epidemiology·Daniel SuissaSamy Suissa
Apr 5, 2014·Archives of Disease in Childhood·Kate Khorsand, Robert Sidbury
Nov 25, 2014·The Journal of Pain : Official Journal of the American Pain Society·Nathaniel KatzRichard Van Inwegen
Aug 5, 2015·Rambam Maimonides Medical Journal·Samy Suissa
Sep 18, 2015·Pharmacoepidemiology and Drug Safety·Diogo MendesFrancisco Batel-Marques
Nov 13, 2015·Journal of Clinical Epidemiology·Pablo Alonso-CoelloGordon H Guyatt
Jun 3, 2017·BMC Medicine·Diogo MendesFrancisco Batel-Marques

❮ Previous
Next ❯

Software Mentioned

SAS Analysis

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Journal of Clinical Epidemiology
Roberto Curiel, Luis Rodríguez-Plaza
Revue médicale de Bruxelles
T RichardA Van Meerhaeghe
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
Mario L de Lemos
© 2022 Meta ULC. All rights reserved